Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Research & Development (2022 - 2025)

Historic Research & Development for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $37.7 million.

  • Stoke Therapeutics' Research & Development rose 6976.36% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.6 million, marking a year-over-year increase of 3676.32%. This contributed to the annual value of $89.1 million for FY2024, which is 839.34% up from last year.
  • Per Stoke Therapeutics' latest filing, its Research & Development stood at $37.7 million for Q3 2025, which was up 6976.36% from $25.9 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Research & Development ranged from a high of $37.7 million in Q3 2025 and a low of $18.3 million during Q1 2022
  • Moreover, its 4-year median value for Research & Development was $21.1 million (2024), whereas its average is $23.0 million.
  • In the last 5 years, Stoke Therapeutics' Research & Development soared by 80.56% in 2023 and then soared by 6976.36% in 2025.
  • Stoke Therapeutics' Research & Development (Quarter) stood at $21.1 million in 2022, then rose by 3.41% to $21.8 million in 2023, then increased by 7.55% to $23.4 million in 2024, then surged by 60.94% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q3 2025, $25.9 million for Q2 2025, and $32.7 million during Q1 2025.